Weekly topotecan and cisplatin (TOPOCIS) as neo-adjuvant chemotherapy for locally-advanced squamous cervical carcinoma: Results of a phase II multicentric study

How often parametrial involvement leads to post-operative adjuvant treatment in locally advanced cervical cancer after neoadjuvant chemotherapy and type C radical hysterectomy?

“…NACT regimens included platinum plus paclitaxel, topotecan, adryamicin and/or ifosfamide, irinotecan, bleomycin in according to different clinical protocols and period of treatment. 4,6,8,12 Stage of disease and grading were assessed using the International Federation of Gynecology and Obstetrics (FIGO) system. 2 Histological subtypes were reported in according to the World Health Organization (WHO) system.…”

“…3 Notwithstanding, accumulating data support the utilization of neoadjuvant chemotherapy (NACT) followed by radical surgery. 4,5 While waiting the results from a multicenter randomized trial comparing chemoradiation versus NACT followed by radical surgery in patients with stage IB2-IIB cervical cancer (EORTC protocol 55994), several investigations have demonstrated that NACT administration is effective in reducing primary tumor diameter, thus allowing radical surgery (type C/type III radical hysterectomy). 4e6 The radical extirpation of the tumor allows an adequate pathological staging and to tailor adjuvant treatment in selected cases at high risk of recurrence.…”

When Does Neoadjuvant Chemotherapy Really Avoid Radiotherapy? Clinical Predictors of Adjuvant Radiotherapy in Cervical Cancer

“…Most authors adopt courses of three cycles of chemotherapy, with a platinum dose ranging from 75 to 100 mg/m 2 compared with 50 mg/ m 2 , as used in GOG 141. 3,5,13,14,23,29 As a result, the total platinum dose ranges between 225 and 300 mg/m 2 before surgery compared with 150 mg/m 2 . With these doses, the reported complete pathological response rate ranges Stage IB2-IIA, FIGO Grade 1 and 2, negative nodes at preoperative radiologic work-up 7 14 Stage IB2-IIA, FIGO Grade 1 and 2, positive nodes at preoperative radiologic work-up 0 25…”

“…Drugs used in combination with cisplatinum included paclitaxel, ifosfamide, topotecan, and adriamycin. 3,13,14 Surgery was planned at 3 weeks from the last cycle of chemotherapy. Response to NACT was evaluated based on response evaluation criteria in solid tumors (RECIST) criteria, clinical examination, MRI, CT scan, or PET-CT scan.…”

Cervical cancer with paraaortic involvement: do patients truly benefit from tailored chemoradiation therapy? A retrospective study on 8 French centers

“…In a retrospective evaluation of patients 258 with PA spread, paclitaxel and carboplatin-based adjuvant 259 chemotherapy led to better outcomes than CRT alone, despite 260 increased toxicity [27]. Neoadjuvant chemotherapy has also been 261 evaluated, with high response rates [28][29][30][31][32]. However, it has never 262 been specifically assessed for cervical carcinoma with PA spread.…”